BioCentury
ARTICLE | Clinical News

Selecta reports Phase II data for SEL-212 to treat gout

June 23, 2017 7:09 PM UTC

Selecta Biosciences Inc. (NASDAQ:SELB) reported data from 60 patients with chronic, severe gout in a Phase II trial showing that 3 monthly injections of SEL-212 followed by 2 monthly challenge injections of pegsiticase alone reduced the proportion of patients experiencing a gout flare in the first month of treatment vs. monthly pegsiticase alone for 5 months (15% vs. 50%). SEL-212 is a non-immunogenic therapy comprising pegsiticase (SEL-037), a pegylated uricase, co-administered with SVP-Rapamycin (SEL-110), a nanoparticle encapsulating the immunomodulator rapamycin.

Selecta also said a majority of patients in the SEL-212 arm who received the minimum effective dose of 0.4/0.08 mg/kg SEL-212 pegsiticase/SVP-Rapamycin maintained control of serum uric acid levels, defined as <6 mg/dL. Additionally, the company said SEL-212 mitigated anti-drug antibodies that resulted in durable control of serum uric acid levels in a dose-dependent manner...